Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Viread · 1 trial · 1 indication
compare the two treatment groups with the goal of achieving HIV-1 RNA levels
compare the safety, efficacy and tolerability of the two treatment regimens through 144 weeks of drug exposure
| Name | Type | Description |
|---|---|---|
| Viread (tenofovir disoproxil fumarate) | DRUG | Tenofovir DF 300 mg tablets once daily |
| Sustiva (Efavirenz) | DRUG | efavirenz capsules 600 mg once daily |
| Epivir (Lamivudine) | DRUG | lamivudine 150 mg tablets twice daily |
| Zerit (Stavudine) Placebo | DRUG | stavudine placebo capsules twice daily |
Inclusion Criteria: * Completed the original 96-weeks of open-label treatment. Willingness to use effective contraception by both males and females while on study treatment and for 30 days following study drugs completion. The ability to understand and sign a written informed consent form, which mu...
Top 20 of 28 competitors
Viread is used for the treatment of HIV infections. It is a small molecule drug being developed by Gilead Sciences, Inc. for this infectious disease indication. Viread is currently in Phase 3 clinical development, meaning it is investigational and has not yet been approved for use.
The specific molecular target of Viread is not disclosed in the available information. It is a small molecule drug being studied for HIV infections, but its mechanism of action has not been specified in the clinical trial data provided.
Viread is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The company is conducting clinical trials to evaluate the drug for the treatment of HIV infections.
Viread is in Phase 3 clinical development. It is an investigational drug for HIV infections and has not been approved by regulatory authorities. The Phase 3 trial has been completed, but the drug remains in clinical development.
Viread has one completed Phase 3 clinical trial, identified as NCT00158821. This study enrolled 180 participants and evaluated the drug in combination with lamivudine and efavirenz compared to stavudine, lamivudine, and efavirenz in antiretroviral-naive, HIV-1-infected patients.
The clinical trial for Viread refers to tenofovir disoproxil fumarate as the drug being studied. This suggests that Viread is the brand name for tenofovir disoproxil fumarate, a small molecule used in the treatment of HIV infections.